WPI: Summary for WATSON PHARMACEUTCLS - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 4:28am EST - Canadian Markets open in 5 hours and 2 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Watson Pharmaceuticals Inc. (WPI)

On Feb 9: 38.10 USD 0.00 (0.00%)

MORE ON WPI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

WATSON PHARMACEUTCLS (NYSE:WPI) Delayed quote data

Last Trade:	38.10 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	38.10
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	43.12

Day's Range:	N/A - N/A
52wk Range:	25.31 - 42.50
Volume:	0
Avg Vol (3m):	930,605
Market Cap:	4.04B
P/E (ttm):	19.64
EPS (ttm):	1.94
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add WPI to Portfolio

Download Data

HEADLINES

•	Iron Safety Hits AMAG Pharmaceuticals
	at Seeking Alpha (Thu, Feb 4)

•	Cephalon Enters Generics Market
	Zacks.com (Tue, Feb 2)

•	Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
	PRNewswire (Tue, Feb 2)

•	Watson signs deal for emergency contraceptive
	AP (Mon, Feb 1)

•	Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
	PRNewswire (Mon, Feb 1)

•	Watson completes $15 million buyout of Eden
	AP (Fri, Jan 29)

•	Watson Completes Acquisition of Eden Biodesign
	PRNewswire (Thu, Jan 28)

•	The Biggest Growth Stocks in Health Care
	at Minyanville.com (Thu, Jan 28)

•	Improving Visibility on Watson
	Zacks.com (Wed, Jan 27)

•	There's Nothing Generic About the Profits
	at Investopedia (Wed, Jan 27)

•	UPDATE - Novartis optimistic on generic Lovenox approval
	at Reuters (Tue, Jan 26)

•	UPDATE - Novartis says on track with generic Lovenox
	at Reuters (Fri, Jan 22)

•	Watson Pharm downgraded by Needham
	Briefing.com (Fri, Jan 22)

More Headlines for WPI...

ANALYST

EPS Est (next year) (Dec-09) :	2.56
EPS Est (in 2 years) (Dec-10) :	3.28
Avg Rec (current)*:	2.7
PEG Ratio:	1.85

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products primarily in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•